Last reviewed · How we verify
NCT03539250
Dose Constraints for the Temporal Lobes of Intensity-modulated Radiotherapy Treatment Plans for Nasopharyngeal Carcinoma
NA trial testing IMRT in Injury; Temporal Region in 350 participants. Status unknown.
31 May 2020
Quick facts
| Lead sponsor | Jiangxi Provincial Cancer Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 350 |
| Start date | 10 June 2018 |
| Primary completion | 31 May 2020 |
| Estimated completion | 31 May 2025 |
Drugs / interventions tested
- IMRT
Conditions studied
- Injury; Temporal Region — all drugs for Injury; Temporal Region →
Sponsor
Jiangxi Provincial Cancer Hospital
Who can join
Adults 18 to 70, any sex, with Injury; Temporal Region. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Radiation-induced temporal lobe injury (TLI) is usually devastating to patients; however, there is a poor understanding of TLI in nasopharyngeal carcinoma (NPC) patients treated with IMRT. Knowledge of the dose tolerance of the TL is essential, in order to predict the safety of intensity-modulated radiotherapy (IMRT) treatment plans. In our previous studies, D1cc (the dose to 1ml of the TL volume) and Dmax (the maximum point dose) were the significant predictors of TLI development. The purpose of this study is to evaluate the feasibility of dose constraints based on D1cc and Dmax for the temporal lobes following IMRT for NPC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03539250
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IMRT
Trials testing the same drug.
- NCT06764680 — Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanc · Phase 2 · recruiting
- NCT06323239 — SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT06364826 — Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma · Phase 2 · not yet recruiting
- NCT06080503 — Phase II Randomized Study of Hypofractionated Versus Conventional Radiotherapy · NA · recruiting
- NCT06314334 — Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma · Phase 2 · recruiting
Other Jiangxi Provincial Cancer Hospital trials
Trials by the same sponsor.
- NCT07314255 — The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma · active not recruiting
- NCT07277764 — Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carc · Phase 2 · recruiting
- NCT06752239 — Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC · Phase 3 · recruiting
- NCT07085988 — Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT06770699 — Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03539250 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangxi Provincial Cancer Hospital
- Last refreshed: 29 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03539250.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing